ApicHope Pharmaceutical Group (300723.SZ) joint venture company, American Arthrosi, may be acquired.

Apichope Pharmaceutical Group(300723.SZ) announced that the US company Arthrosi, in which the company has a stake, has received the relevant agreement terms from Sobi USA. Sobi USA plans to acquire 100% of Arthrosi's equity with an initial payment of 950 million US dollars (approximately 6.713 billion RMB) and up to 550 million US dollars (approximately 3.887 billion RMB) in clinical, registration, and sales milestone payments. The transaction is subject to approval by Arthrosi shareholders, and after the completion of the transaction, the company will no longer hold any stake in Arthros. The announcement stated that the company holds 100% market rights for AR882 in China, as well as the exclusive global production and supply rights for providing AR882 to Arthrosi. Currently, AR882 is undergoing crucial Phase III clinical trials.